Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Fig. 2

Response according to European League Against Rheumatism Criteria. csDMARD conventional synthetic disease-modifying antirheumatic drug, bDMARD biologic disease-modifying antirheumatic drug

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us